Cargando…

The availability and validity of safety information of over the counter herbal products for use in diabetes in Sri Lanka: A cross sectional study

AIMS: There is an increase of over-the-counter (OTC) herbal products for use in diabetes mellitus. The aim of this study is to evaluate the safety information provided with OTC herbal remedies intended for diabetic patients in Sri Lanka and to assess the completeness of the information provided. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Medagama, Arjuna Bandara, Widanapahirana, Heshan, Prasanga, Tharindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGEYA 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665020/
https://www.ncbi.nlm.nih.gov/pubmed/26649230
http://dx.doi.org/10.5455/jice.20151104093108
Descripción
Sumario:AIMS: There is an increase of over-the-counter (OTC) herbal products for use in diabetes mellitus. The aim of this study is to evaluate the safety information provided with OTC herbal remedies intended for diabetic patients in Sri Lanka and to assess the completeness of the information provided. METHODS: Inclusion criteria consisted of OTC herbal remedies meant for use in diabetes. They were bought from local Sri Lankan supermarkets and non-ayurvedic pharmacies and product information regarding the risk of hypoglycemia, precautions for use, adverse events, dose, and interactions were assessed using a scoring system. The accuracy of the information was then compared against published data. RESULTS: 11 products fulfilled the inclusion criteria. Five products contained a single constituent and five contained more than one. None had complete and accurate safety information according to our criteria. None specifically warned against the risk of hypoglycemia. 9 out of 11 products (81.8%) carried ≤3 items of the five essential factual information we expected. Hypoglycemic coma, gastrointestinal symptoms, hepatotoxicity, carcinogenesis, and interactions causing elevated drug levels of Carbamazepine were some of the safety information that was missing. CONCLUSIONS: Key safety information was absent in most products. Regulation of sale, provision of key safety information and adverse event reporting should be a priority.